



NEWS RELEASE



FOR IMMEDIATE RELEASE

November 29, 2021

INDEPENDENT PROGRAM ADMINISTRATOR ISSUES ANNUAL REPORT

Major League Baseball (MLB) and the Major League Baseball Players Association (MLBPA) today released the annual public report from the Joint Drug Prevention and Treatment Program's Independent Program Administrator. The Joint Drug Prevention and Treatment Program calls for a public report to be issued each year.

The accompanying report from the Independent Program Administrator, Thomas M. Martin, Ph.D., covers the period from the beginning of the 2020-2021 off-season through the end of Major League Baseball's 2021 Postseason. In addition, the report includes the total number of in-season tests and off-season tests conducted during the previous five (5) years.

###

Contact: Michael Teevan or Donald Muller, Major League Baseball, (212) 931-7878, mlbpressbox.com, [@MLB_PR](https://twitter.com/MLB_PR);
Chris Dahl, Major League Baseball Players Association, (212) 826-0808, mlbplayers.com, [@MLB_PLAYERS](https://twitter.com/MLB_PLAYERS).



2021 Public Report of Major League Baseball's Joint Drug Prevention and Treatment Program

This report covers the time from the beginning of the 2020-2021 off-season to the end of the 2021 post-season (the "2021 Reporting Period"). Additionally, this report also includes the total number of in-season and off-season tests conducted during the previous five years. As per agreement between the Office of the Commissioner of Baseball and the Major League Baseball Players Association, the following report is specific to Players on the 40-man rosters for Major League Baseball Clubs.

- 1) The total number of drug tests that were conducted during the 2021 Reporting Period was 8,436. All of these tests were urine samples that were collected and analyzed for Performance Enhancing Substances, Stimulants, DHEA, Diuretics, Masking Agents, and Drugs of Abuse.
- 2) Six (6) adverse analytical findings were reported by the Montreal Laboratory and resulted in discipline. Of those, five (5) were for Performance Enhancing Substances and one (1) was for a Stimulant. The substances reported were as follows:

Performance Enhancing Substances (5)

Dehydrochloromethyltestosterone (DHCMT): 2
Nandrolone: 1
Stanozolol: 1
Testosterone: 1

Stimulants (1)

Amphetamine: 1

- 3) Eighty-four (84) Therapeutic Use Exemptions were granted. The categories of medications were as follows:

Attention Deficit Hyperactivity Disorder: 79
Hypertension: 1
Altitude sickness: 1
Sleep disorder: 1
Hypogonadism: 2



4) The total number of drug tests that were conducted during the previous five (5) years was 45,973 tests. Of this total number, the number of in-season tests that were conducted was 38,646. The number of off-season tests that were conducted was 7,327. The year-by-year breakdown of the testing is documented below:

YEAR	TOTAL TESTS	IN-SEASON TESTS	OFF-SEASON TESTS
2017	10,237	9,687	550
2018	11,526	9,437	2,089
2019	11,619	9,561	2,058
2020	4,155	2,076	2,079
2021	8,436	7,885	551
TOTAL	45,973	38,646	7,327

Respectfully submitted,

Thomas M. Martin

Thomas M. Martin, Ph.D.
Independent Program Administrator
Major League Baseball's Joint Drug Prevention and Treatment Program